PREPARATION AND ANTITUMOR ACTIVITIES OF MITOMYCIN-C BETA-(1-]6)-BRANCHED (1-]3)-BETA-D-GLUCAN CONJUGATE

Citation
S. Usui et al., PREPARATION AND ANTITUMOR ACTIVITIES OF MITOMYCIN-C BETA-(1-]6)-BRANCHED (1-]3)-BETA-D-GLUCAN CONJUGATE, Biological & pharmaceutical bulletin, 17(9), 1994, pp. 1165-1170
Citations number
25
Categorie Soggetti
Pharmacology & Pharmacy
ISSN journal
09186158
Volume
17
Issue
9
Year of publication
1994
Pages
1165 - 1170
Database
ISI
SICI code
0918-6158(1994)17:9<1165:PAAAOM>2.0.ZU;2-Y
Abstract
The conjugate of mitomycin C (MMC) with carboxymethylated schizophylla n (CMSPG) which was prepared from monochloroacetic acid and schizophyl lan (SPG), a beta-(1-->6)-branched (1-->3)-beta-D-glucan from Schizoph yllum commune FRIES, was synthesized by using 1-ethyl-1-3-(3-dimethyla minopropyl)-carbodimide. The degree of the substitution of carboxymeth yl groups in CMSPG was estimated as approximately 0.87, and locations of carboxymethyl groups in CMSPG were predominantly determined at 0-4, 0-6, and 0-4, 6 positions in glucose residues, The contents of MMC in the eonjugate were estimated to be between 8 and 12% (w/w). The conju gate showed successive monoexponential liberation, with a half-life of 7.2 h. Although the in vitro cytotoxicity of the conjugate against L1 210 leukemia cells was similar to that of MMC when the cells were expo sed for 21 and 48 h, the 50% growth-inhibitory concentration of the co njugate for L1210 was two times higher than that of MMC with exposure for 12 h. The antitumor activity of the conjugate against subcutaneous ly implanted sarcoma 180 solid tumor in mice by intraperitoneal (i.p.) administration was similar to that of MMC at a dose of 1.5 mg eq MMC per kg per d for both 7 times of continuous administration and 4 times of intermittent administration. However, the reduction in the number of leukocytes in the peripheral blood, which was the side effect of MM C, was suppressed by the intermittent administration of the conjugate. The conjugate maintained the ability to induce the tumor regressing f actor and the neutrophil chemotactic factor in the serum.